GAA Brain Booster? The 6-Week Trial Result Is Complicated
GAA, the creatine precursor sold as a brain booster, just got its first serious human test. In a six-week, double-blind trial of 58 healthy adults, it produced some faster reaction times and a scattering of mood and stress signals. Most cognitive tests, however, showed nothing, and many of the headline results were only trends. Safety markers looked fine, but the study was small, exploratory, and had no creatine-only comparison group. Here is what it really shows, who it might suit, and why the verdict is mixed.
Creatine's Precursor Beat Creatine for Grip Strength in Over-65s
A small trial in adults over 65 found that guanidinoacetic acid (GAA), the direct precursor of creatine, improved grip strength more than creatine monohydrate. The catch is that it was an 8-week pilot with just 21 completers, no exercise program, and a confidence interval that barely cleared zero. GAA also showed greater myostatin suppression and BIA-measured gains in muscle-related indices, though those readings may partly reflect hydration. Homocysteine is the safety question to watch, since GAA consumes methyl groups and has raised it in other studies. Here is what the study found, what it can't tell us, and why creatine monohydrate is still the proven default.